@article {1504088,
	title = {Short-term Outcomes After Very Low-Dose Intravitreous Bevacizumab for Retinopathy of Prematurity},
	journal = {JAMA Ophthalmol},
	year = {2020},
	month = {2020 Apr 23},
	abstract = {Importance: Intravitreous bevacizumab (0.25 mg to 0.625 mg) is commonly used to treat type 1 retinopathy of prematurity (ROP), but there are concerns about systemic toxicity, particularly the risk of neurodevelopmental delay. A much lower dose may be effective for ROP while reducing systemic risk. Previously, after testing doses of 0.25 mg to 0.031 mg, doses as low as 0.031 mg were found to be effective in small cohorts of infants. Objective: To find the lowest dose of intravitreous bevacizumab effective for severe ROP. Design, Setting, and Participants: Between April 2017 and May 2019, 59 premature infants with type 1 ROP in 1 or both eyes were enrolled in a masked, multicenter, dose de-escalation study. In cohorts of 10 to 14 infants, 1 eye per infant received 0.016 mg, 0.008 mg, 0.004 mg, or 0.002 mg of intravitreous bevacizumab. Diluted bevacizumab was prepared by individual research pharmacies and delivered using 300-{\textmu}L syringes with 5/16-inch, 30-guage fixed needles. Analysis began July 2019. Interventions: Bevacizumab intravitreous injections at 0.016 mg, 0.008 mg, 0.004 mg, or 0.002 mg. Main Outcomes and Measures: Success was defined as improvement by 4 days postinjection and no recurrence of type 1 ROP or severe neovascularization requiring additional treatment within 4 weeks. Results: Fifty-five of 59 enrolled infants had 4-week outcomes completed; the mean (SD) birth weight was 664 (258) g, and the mean (SD) gestational age was 24.8 (1.6) weeks. A successful 4-week outcome was achieved for 13 of 13 eyes (100\%) receiving 0.016 mg, 9 of 9 eyes (100\%) receiving 0.008 mg, 9 of 10 eyes (90\%) receiving 0.004 mg, but only 17 of 23 eyes (74\%) receiving 0.002 mg. Conclusions and Relevance: These data suggest that 0.004 mg may be the lowest dose of bevacizumab effective for ROP. Further investigation is warranted to confirm effectiveness of very low-dose intravitreous bevacizumab and its effect on plasma vascular endothelial growth factor levels and peripheral retinal vascularization.},
	issn = {2168-6173},
	doi = {10.1001/jamaophthalmol.2020.0334},
	author = {Wallace, David K and Kraker, Raymond T and Freedman, Sharon F and Crouch, Eric R and Bhatt, Amit R and Hartnett, M Elizabeth and Yang, Michael B and Rogers, David L and Hutchinson, Amy K and VanderVeen, Deborah K and Haider, Kathryn M and Siatkowski, R Michael and Dean, Trevano W and Beck, Roy W and Repka, Michael X and Smith, Lois E and Good, William V and Kong, Lingkun and Cotter, Susan A and Holmes, Jonathan M and Pediatric Eye Disease Investigator Group (PEDIG)}
}
